Stocks swiftly recovered from the DeepSeek-driven sell-off early in the week but came under pressure on Friday amid concerns ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

January 2025 saw strong gains in US and international equities, led by Health Care sector performance and concerns about inflation. Click for my monthly recap.

CNBC's Jim Cramer on Friday walked investors through an earnings-heavy week, highlighting reports from Amazon, Alphabet, Eli ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in the ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...